NUTRACEUTICAL INGREDIENT · US MARKET
LONGEVITY
BLACK GINSENG CORE™
Rare ginsenosides + NMN · patent pending
A two-part ingredient for the SIRT1 and NAD⁺ axis: Botalys black ginseng, steam-converted so that more than 80% of its ginsenosides are rare forms, paired with β-NMN, a precursor of NAD⁺.
Positioned for healthy aging, for the US market. The combination has not been tested in a clinical trial yet; each component has its own published data, shown below.
700 MG
Daily dose
20 MG
Rare ginsenosides a day
500 MG
NMN a day
What is it
SIRT1 is a NAD⁺-dependent enzyme involved in DNA repair, autophagy, mitochondrial function and inflammatory signalling. Its activity depends on two things: how much of the enzyme the cell makes, and how much NAD⁺ is available to run it. NAD⁺ levels decline with age.
Black Ginseng Core addresses both. Its ginseng component supplies rare ginsenosides such as Rg5, Rk1 and Rg3, which raised SIRT1 expression or activity in published cell and animal studies. Its NMN component supplies the NAD⁺ precursor, which raised blood NAD⁺ in human trials. The ginseng is the same aseptically grown, steam-cooked root as Red Ginseng HRG80™.
COMPOSITION
GINSENG + NMN
GINSENG
200 MG/DAY
STATUS
PATENT PENDING
MARKET
UNITED STATES
NAD⁺ SUPPLY
Oral NMN raised blood NAD⁺ versus placebo in a randomized, double-blind trial in 80 healthy adults aged 40 to 65, at 300, 600 and 900 mg a day, with the highest levels at 600 and 900 mg. The 500 mg in this formula sits inside that range.
HUMAN EVIDENCE, NMN
STRONG
Several randomized trials on NMN, not on this formula
SIRT1 EXPRESSION
Rare ginsenosides Rg3 and Rg5 increased SIRT1 expression or activity in cell and animal models of oxidative, inflammatory and metabolic stress. This has not been measured in humans, nor on this ginseng.
PRECLINICAL EVIDENCE
EMERGING
Published studies on isolated ginsenosides
THE GINSENG, TESTED ALONE
Tested alone as HRG80™ at the same 200 mg daily dose, the ginseng component reduced perceived stress and negative affect and shortened planning time versus placebo in 149 moderately stressed adults over three weeks.
HUMAN EVIDENCE, GINSENG
STRONG
3 randomized, double-blind trials on the ginseng component
Grades describe each component’s own published data. STRONG, significant in two or more randomized, double-blind, controlled trials. MODERATE, in one such trial. EMERGING, preclinical data only. No trial has tested the combination yet.
NMN RAISES BLOOD NAD⁺ IN HEALTHY ADULTS
In a 60-day randomized, double-blind, placebo-controlled trial in 80 healthy adults aged 40 to 65, NMN at 300, 600 and 900 mg a day increased blood NAD⁺ at days 30 and 60 compared with placebo and with baseline. Levels were highest at 600 and 900 mg, and walking distance in the six-minute test improved versus placebo.
This is published work on NMN, not on Black Ginseng Core. Results across NMN trials are not uniform: another 60-day trial at 300 mg found no significant rise in blood NAD⁺.
Randomized, multicenter, double-blind, placebo-controlled, parallel groups. 80 healthy adults aged 40 to 65, 60 days.
Placebo or 300, 600 or 900 mg NMN once daily. Blood NAD⁺, six-minute walk test, SF-36, safety.
Blood NAD⁺ up versus placebo and baseline at days 30 and 60 in all NMN groups (p ≤ 0.001). No safety issues reported up to 900 mg a day.
Yi et al., GeroScience 2023. NCT04823260.
THE GINSENG COMPONENT AT THE SAME 200 MG
The ginseng in Black Ginseng Core was tested alone, as HRG80™, at 200 mg a day in 149 moderately stressed adults at UCLouvain. Over three weeks it reduced perceived stress and negative affect more than placebo and shortened planning time. This supports the ginseng component; it says nothing yet about the combination.
Randomized, double-blind, placebo-controlled, parallel groups. 149 adults aged 18 to 60 with moderate perceived stress, 142 analysed.
HRG80 200 mg/day or placebo for 21 days. PSS −4.3 vs −2.7 (p = 0.040); PANAS negative affect −2.6 vs −1.1 (p = 0.032).
Dormal et al., Nutrients 2025; 17: 955. NCT06414486.
Rare ginsenosides act on how much SIRT1 the cell makes and how active it is; NMN supplies the NAD⁺ it needs to run. The grey labels show where each link has been measured.
This table separates what each component has shown on its own from what the formula has shown. The formula itself has no trial yet: that is the last row, stated as such.
Until a combined study exists, Black Ginseng Core rests on two independent bodies of evidence and on the established role of NAD⁺ in SIRT1 function. A formulator should present it that way, and so do we.
FORMULATION
DAILY DOSE
700 MG FULL DOSE
200 mg ginseng with 20 mg rare ginsenosides, plus 500 mg NMN.
200 MG GINSENG
The dose tested alone in the largest ginseng trial.
500 MG NMN
Inside the 300 to 900 mg range tested in NMN trials.
No study has tested the combination. In the EU the formula cannot be sold as is: NMN is not yet authorised as a novel food, and the first positive EFSA opinion (May 2026) covers up to 300 mg a day.
Samples, specifications and the US claims guide are available to qualified brands and formulators.
REQUEST A SAMPLE
REQUEST THE HEALTH CLAIMS MATRIX


